EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus

EXEL beats Q1 EPS estimates on lower costs and buybacks but misses on revenues; Cabometyx sales lag estimates as pipeline progress and new buybacks stay in focus.